Yasmin 0.03 mg / 3 mg film-coated tablets

국가: 아일랜드

언어: 영어

출처: HPRA (Health Products Regulatory Authority)

유효 성분:

Drospirenone; Ethinylestradiol

제공처:

Bayer Limited

ATC 코드:

G03AA; G03AA12

INN (International Name):

Drospirenone; Ethinylestradiol

복용량:

0.03 mg/3 milligram(s)

약제 형태:

Film-coated tablet

처방전 유형:

Product subject to prescription which may be renewed (B)

치료 영역:

Progestogens and estrogens, fixed combinations; drospirenone and ethinylestradiol

승인 상태:

Marketed

승인 날짜:

2000-10-27

환자 정보 전단

Page
1
of
18
BP23003_REC20788+REC30040
PACKAGE LEAFLET: INFORMATION FOR THE USER
YASMIN 0.03 MG/3 MG FILM-COATED TABLETS
ethinylestradiol/drospirenone
_ _
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible
side effects not listed in this leaflet. See section 4.
IMPORTANT THINGS TO KNOW ABOUT COMBINED HORMONAL CONTRACEPTIVES
(CHCS):
-
They are one of the most reliable reversible methods of contraception
if used correctly.
-
They slightly increase the risk of having a blood clot in the veins
and arteries, especially in the
first year or when restarting a combined hormonal contraceptive
following a break of 4 or more
weeks.
-
Please be alert and see your doctor if you think you may have symptoms
of a blood clot (see
section 2 “Blood clots”).
WHAT IS IN THIS LEAFLET
1.
What Yasmin is and what it is used for
........................................................... 2
2.
What you need to know before you take Yasmin
............................................ 2
When you should not use Yasmin
................................................................... 2
Warnings and precautions
................................................................................
4
BLOOD CLOTS
..............................................................................................
5
Yasmin and cancer
.........................................................................................
10
Psychiatric disorders
......................................................................................
10
Bleeding between periods
..............................................................................
10
What to do if no bleeding occurs during t

제품 특성 요약

Health Products Regulatory Authority
13 November 2023
CRN00DFP3
Page 1 of 14
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Yasmin 0.03 mg / 3 mg film-coated tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 0.030 mg ethinylestradiol and 3 mg
drospirenone
Excipient with known effect: lactose 46 mg (as lactose monohydrate
48.17 mg)
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Film-coated tablet
Light yellow, round tablets with convex faces, one side marked with
the letters "DO" in a regular hexagon
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Oral contraception
The decision to prescribe Yasmin should take into consideration the
individual woman’s current risk factors, particularly those
for venous thromboembolism (VTE), and how the risk of VTE with Yasmin
compares with other combined hormonal
contraceptives (CHCs), see sections 4.3 and 4.4.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
_METHOD OF ADMINISTRATION_
Oral use
_POSOLOGY_
HOW TO TAKE YASMIN
The tablets must be taken every day at about the same time, if
necessary with a little liquid, in the order shown on the blister
pack. One tablet is to be taken daily for 21 consecutive days. Each
subsequent pack is started after a 7-day tablet-free interval,
during which time a withdrawal bleed usually occurs. This usually
starts on day 2-3 after the last tablet and may not have
finished before the next pack is started.
HOW TO START YASMIN

No preceding hormonal contraceptive use (in the past month)
Tablet-taking has to start on day 1 of the woman's natural cycle (i.e.
the first day of her menstrual bleeding).

Changing from a combined hormonal contraceptive (combined oral
contraceptive (COC), vaginal ring, or
transdermal patch)
The woman should start with Yasmin preferably on the day after the
last active tablet (the last tablet containing the active
substances) of her previous COC, but at the latest on the day
following the usual tablet-free or placebo tablet interval of her